Gilead will present 28 studies at IDWeek 2026, covering Bixlenvo treatment outcomes, early real-world Yeztugo adoption and final Phase 1b findings for the investigational herpes medicine GS-1179. The programme examines how recently approved HIV treatments perform in practice while advancing a separate long-acting antiviral candidate.
Gilead Sciences has expanded royalty-free licensing agreements with six generic manufacturers to cover investigational once-yearly lenacapavir for HIV prevention while the Phase 3 PURPOSE 365 study is still underway. The decision deliberately moves manufacturing and access planning ahead of regulatory certainty, potentially shortening the years-long delay that has historically separated pharmaceutical innovation from broad availability
Gilead Sciences has expanded six royalty-free licenses to cover investigational once-yearly lenacapavir for HIV prevention, starting manufacturing preparations before the pivotal PURPOSE 365 study has delivered its results.
Gilead Sciences has secured U.S. Food and Drug Administration approval for Bixlenvo, a once-daily tablet combining bictegravir and lenacapavir for virologically suppressed adults with HIV, including patients whose resistance or treatment history has kept them on complex multi-tablet regimens.
Gilead and Merck’s weekly HIV pill preserved suppression in two Phase 3 trials, strengthening the case for regulatory filings.
Read how Gilead’s once weekly oral Yeztugo filing could reshape HIV prevention, PrEP adherence and long acting therapy competition.
Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.
Gilead’s CROI 2026 data highlight lenacapavir’s evolution into a platform for HIV treatment and prevention. Explore what this changes for clinicians and regulators.